Multiple Sclerosis Outcomes and Prognostics Team

Research Overview

The Outcomes and Prognostics team is part of the Multiple Sclerosis and Neuroimmunology Clinical Research Group, and co-headed by Dr Tomas Kalincik, Dr Vilija Jokubaitis, and Dr Melissa Gresle.

The team's research revolves around multiple sclerosis outcomes, including real-world effect of different treatment strategies, definition of disease outcomes and long-term effect of immunomodulatory therapies. The scope comprises prognostic markers, including demographic, clinical and genetic predictors of disease severity, with a strong focus on indivdualised therapy.

The team's research interests span neurology and biology of multiple sclerosis and neuroimmunology as well as advanced statistical methodology.  A number of  opportunities exist for honours students, higher degree students (including master and PhD programs), research fellows and research associates. We offer hands-on training in the neurology of autoimmune diseases and analytics of large observational data.

The team's past research projects:

  • long-term multiple sclerosis outcomes in patients treated with injectable immunomodulatory therapies
  • comparative studies of outcomes in patients treated with first- and second-generation disease modifying therapies
  • activity of multiple sclerosis after discontinuation of natalizumab
  • epidemiology and impact of multiple sclerosis relapses
  • definition of disability outcomes in multiple sclerosis
  • phenotypic characterisation of multiple sclerosis



The core of the team's work is based on large observational registries, in particular MSBase, a longitudinal global cohort study of multiple sclerosis, which involves 117 collaborating centres at 35 countries ( The team leads or participates in a number of collaborative research projects with our partners including Karolinska Institute, Harvard Medical School, Cambridge University or University of Basel, as well as industry.


The team's research projects are funded by the National Medical and Health Research Council, Multiple Sclerosis Research Australia, Multiple Sclerosis Society (UK), Biogen and Merck.

Research Opportunities

This research project is available to PhD students to join as part of their thesis.
Please contact the Research Group Leader to discuss your options.

Research Publications

  1. Lorscheider J, Buzzard K, Jokubaitis V, Spelman T, Havrdova E,… Kalincik T, on behalf of the MSBase Study Group (in press) Defining secondary progressive multiple sclerosis. Brain
  2. Jokubaitis V, Spelman T, Kalincik T, Lorscheider  J, Havrdova E, Horakova D, et al., on behalf of the MSBase Study Group (in press) Predictors of long-term disability accrual in relapse-onset multiple sclerosis. Ann Neurol
  3. Stewart T, Spelman T, Havrdova E… Kalincik T (in press) Contribution of different relapse phenotypes to disability in multiple sclerosis. Mult Scler
  4. Spelman T, Kalincik T, Jokubaitis V, Zhang A, Pellegrini F, Wiendl H et al., on behalf of the MSBase Study Group and the TOP investigators (in press) Comparative  efficacy of  first-line natalizumab versus IFN╬▓ or glatiramer acetate in relapsing-remitting MS. Neurology: Clinical Practice
  5. Kalincik T, Cutter G, Spelman T, Jokubaitis V, Havrdova E, Horakova D, et al., on behalf of the MSBase Study Group (2015) Defining reliable disability outcomes in multiple sclerosis. Brain 138:3287-98
  6. Warrender-Sparkes M, Spelman T, Izquierdo G, ... Kalincik T and Jokubaitis V, on behalf of the MSBase Study Group (in press) The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. Mult Scler
  7. Jokubaitis VG, Spelman T, Kalincik T, Izquierdo G, Grand’Maison F, Duquette P et al., on behalf of the MSBase Study Group (2015) Predictors of disability worsening in clinically isolated syndrome. Ann Clin Transl Neurol, 2(5):479-91
  8. Spelman T, Kalincik T, Zhang A, Pellegrini F, Wiendl H, Kappos L, et al., on behalf of the MSBase and TOP investigators (2015) Comparative efficacy of switching to natalizumab in active multiple sclerosis. Ann Clin Transl Neurol 2(4):373-87
  9. Kalincik T, Horakova D, Spelman T, Jokubaitis V, Trojano M, Lugaresi A, et al., on behalf of the MSBase Study Group (2015) Switch to natalizumab vs fingolimod in active relapsing-remitting multiple sclerosis. Ann Neurol 77(3):425-35
  10. He A, Spelman T, Jokubaitis VG, Havrdova E, Horakova D, Trojano M, . . . Kalincik T, on behalf of the MSBase Study Group (2015) Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis. JAMA Neurology 72(4):405-413
  11. Kalincik T, Jokubaitis V, Izquierdo G, Duquette P, Girard M, Grammond P, et al., on behalf of the MSBase Study Group (2015) Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis. Mult Scler 21(9):1159-71
  12. Kalincik T, Buzzard K, Jokubaitis V, Trojano M, Izquierdo G, Duquette P, et al., on behalf of the MSBase Study Group (2014) Risk of relapse phenotype recurrence in multiple sclerosis. Mult Scler 20(11), 1511-1522
  13. Jokubaitis VG, Li V, Kalincik T, Izquierdo G, Hodgkinson S, Alroughani R et al., on behalf of the MSBase Study Group (2014) Fingolimod after Natalizumab and the risk of short-term relapse. Neurology 82:1-8
  14. Kalincik T, Vivek V, Jokubaitis VG, Lechner Scott J, Trojano M, Izquierdo G et al., on behalf of the MSBase Study Group (2013) Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. Brain 136:3609-3617
  15. Kalincik T, Spelman T, Trojano M, Duquette P, Izquierdo G et al., on behalf of the MSBase Study Group (2013) Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis. PLoS One 8:e63480

Research Projects

Faculty Research Themes


School Research Themes

Neuroscience & Psychiatry

Key Contact

For further information about this research, please contact Dr Tomas Kalincik

Department / Centre

Medicine and Radiology